

Fucosidosis: clinical and molecular findings of Turkish patients

Merve Emecen Şanlı¹*, Serap Uysal²*

¹Department of Pediatric Inborn Errors of Metabolism, İstanbul Basakşehir City Hospital, İstanbul; ²Department of Pediatric Neurology, Koç University Medical Faculty, İstanbul, Turkey.

ABSTRACT

Background. Fucosidosis is a rare, autosomal recessive lysosomal storage disease caused by alpha L- fucosidase enzyme deficiency in all tissues. Here, we identify a patient with a novel homozygous pathogenic variant and atypical clinical findings and summarized the clinical and molecular features of Turkish patients reported in the literature and present.

Case. The patient was born to consanguineous parents at the 28th week of gestation. He had developmental delay that was attributed to prematurity. At he age of 2.5 years, brain magnetic resonans imaging revealed hyperintensities of symmetrical periventricular, subcortical, centrum semiovale and corona radiata regions on T2 and FLAIR weighted images. He developed seizures and showed developmental regression at he age of 3,5 years. Beside, coarse facial features and hepatomegaly were detected on phsyical examination. Lysosomal enzyme analysis revealaed alfa fucosidase deficiency and molecular genetic analysis identified a novel homozygous pathogenic p. Lys431 fs variant in *FUCA1* gene.

Conclusions. In Turkish patients no distinguishable clinical and radiologic finding could be established. Molecular analysis was performed in few patients. Increasing of molecular and biochemical facilities might enable to make diagnosis and increase the prevalence of the disease in countries with high rate of consanguineous marriages. Moreover, it will provide genetic counseling, and enlighten the therapeutic effects of hematopoietic stem cell transplantation.

Key words: fucosidosis, *FUCA1*, developmental regression, coarse face.

Fucosidosis is a very rare autosomal-recessive lysosomal storage disease. Deficiency of α -L-fucosidase due to biallelic pathogenic variants in *FUCA1* gene leads to the accumulation of glycoproteins, glycolipids, oligosaccharides, and mucopolysaccharides in various tissues including both the central and peripheral nervous system.¹

Clinical manifestation are typically characterized by delayed motor and cognitive functions followed by progressive neurological deteriorations, associated with systemic features of a coarse face, dysostosis multiplex, recurrent

respiratory infections, angiokeratoma corporis diffusum, organomegaly, ocular abnormalities, hearing loss, growth retardation, contractures, spasticity, seizures and consequently early death.²⁻⁴

The diagnosis is confirmed by demonstration of reduced enzyme activity and, preferably, mutation analysis.^{5,6} Hematopoietic stem cell transplantation (HSCT) may reduce the severity and slow the progression of the neurological features.⁷

Here we present a patient with a novel pathogenic mutation and atypical clinical findings and identify an overview of Turkish patients in the literature.

✉ Merve Emecen Şanlı
merveemecan@gmail.com

Received 22nd October 2021, revised 18th January 2022,
accepted 7th April 2022.

Case Report

Our patient was born as a first child to consanguineous parents at the 28th gestation week with the weight of 1150 gr by cesarean delivery. He was admitted to the neonatal intensive care unit and developed grade I-II intracranial bleeding. During his follow up, developmental milestones were delayed. Holding his head in a prone position was possible at the age of 8 months and he developed sitting without support and speech at 12 months. He had recurrent respiratory infections and his sweat chloride test was performed and found abnormal. However cystic fibrosis (CF) molecular analysis was normal. He underwent an inguinal hernia operation at 1,5-year-old and he was consulted to the Department of Orthopedics for kyphosis. At the age of 2,5 years, brain magnetic resonance imaging (MRI) showed hyperintensities of symmetrical periventricular, subcortical, centrum semiovale and corona radiata regions on T2 and FLAIR weighted images (Fig. 1). Then he developed seizures and after one week he showed rapid developmental regression as losing his sitting and speech abilities. Whole exome sequencing (WES) analysis was planned, and he was

referred to our clinic at the age of 3,5 years. On physical examination, his anthropometrics were as follows: height: 92cm (3p), weight: 13.5 kg (12p) head circumference: 50 cm (35p). He had a coarse face with broad nasal bridge, hypertelorism, wide ala nasis, and minimal hepatomegaly. He was not able to cooperate and had a lack of eye contact and no response to social interaction. He had axial hypotonicity, he was not able to sit without support, he had poor head control on traction and spasticity in all four extremities. He also had dysostosis multiplex, kyphosis and pectus carinatum (Fig. 2). Physical examination and clinical findings indicate an oligosaccharidosis and his WES analysis revealed a novel pathogenic homozygous c. 1290_1299delGAAGTGGTCC (p. Lys431 fs) variant in FUCA1 gene that may result in a frameshift mutation. Leukocyte enzyme analysis showed almost a non-detectable enzyme levels which confirmed the diagnosis. Transthoracic echocardiography and fundoscopic evaluation were normal, however audiological assessment identified bilateral hearing loss.

Written informed consent was obtained from the parents of the child.





Fig. 1. Magnetic resonance imaging (MRI) T2-weighted axial images showing almost symmetrical hyperintensities involving the peritrigonal, periventricular, subcortical, centrum semiovale, corona radiata regions.




Fig. 2. Dysostosis multiplex of hands and vertebra. **a.** indicates irregularities of proximal metacarpals and bullet shaped distal phalanges; **b.** indicates anterior beaking of the vertebral body and gibbus deformity.

Discussion

Alpha L-fucosidase enzyme is a homotetramer composed of subunits of different masses (50 to 60 kDa), which causes variations in N-glycosylation and proteolytic processing.^{19,20} As a result of the hydrolytic enzyme deficiency, incomplete catabolism of N- and O-glycosylproteins leads to the accumulation of fucose-containing glycolipids and glycoproteins in various tissues and urine. Fucose (C₆H₁₂O₆), is found in most of the plasma glycoproteins in the mucopolysaccharides and mucolipids of various human and animal tissues.⁸

Fucosidosis is a very rare disease with a very low incidence of <1/200000. To date, around 120 patients were identified.⁹⁻¹¹ The highest incidence has been described in Italy, Mexico, Colorado and Cuba.^{9,12} We could obtain clinical and molecular manifestations of 14 Turkish patients after a detailed literature investigation. The mean age of the patients was 6 years and male/female ratio was 9/5. Consanguinity was present in 11/12 families. 9 (81%) patients had developmental delay. All patients had coarse facial features, intellectual delay, developmental delay and developmental regression. Apart from one patient, all patients (90%) had growth retardation. Recurrent

respiratory infections were present in 63% of the patients. Angiokeratoma corporis diffusum and dysostosis multiplex were seen in 54% of the patients. Seizure and organomegaly were accompanied in 27% of the patients. Our patient was the only patient with hearing loss involvement. Brain MRI findings of 12 patients demonstrated periventricular and, subcortical white matter abnormalities in 7 and 4 patients, cortical and midbrain involvement in 1 and 2 patients respectively. Hypointensities on T2 and hyperintensities on T1- weighted images of globus pallidus was detected in 4 patients and hypointense areas were shown in 3 patients. Cerebellar volume increasing was demonstrated in 3 patients in early stage of the disease. (Alpha L- fucosidase enzyme analysis was performed in 9 patients and low levels were detected in a total of the patients. Only 3 patients underwent molecular analysis of the FUCA1 gene and pathogenic mutations were determined in all of the patients.¹³⁻²⁰

Willems et al.² and Wali et al.⁷ reported clinical and molecular findings of 77 and 89 patients respectively. Comparison of clinical features of those patients with Turkish patients is shown in Table I. Our findings were more consistent with Willems et al.² report. Almost all of the percentages of clinical manifestations in the

Table I. Comparison of prevalence of clinical findings in the literature.

	Wiliam et al. ²	Wali et al. ⁷	Turkish Cases
Mental retardation	73 (95%)	50-60%	14 (100%)
Neurologic regression	68 (88%)	50-60%	14 (100%)
Coarse face	61 (79%)	70-80%	11 (100%)
Growth retardation	60(78%)	30-40%	10 (90%)
Recurrent infections	60 (78%)	30-40%	7 (63%)
Dysostosis multiplex	45 (58%)	50-60%	6 (54%)
Angiokeratoma	40 (52%)	40-50%	6 (54%)
Seizure	29 (38%)	10-20%	3 (27%)
Organomegaly	23 (30%)	30-40%	3 (27%)
Hearing loss	9 (12%)	10-20%	3 (27%)
Hernia	7 (9%)	-	1 (9%)
Ophthalmologic findings	5 (6%)	<10%	-

study by Wali et al.⁷ were lower than the Willems et al.² 's and ours. Particularly growth retardation was present in 30-40% of the patients in the report by Wali et al.⁷, however, in Willems et al.² and in our report the percentages were 78% and 90% respectively. Growth retardation becomes more prominent with age and severity of the disease. The difference in the growth retardation rates in different studies might be associated with the difference in age and disease severity. The most common finding was intellectual disability in Willems et al.² and our report, however it was coarse face in Wali et al.⁷ Hearing loss, hernia and ophthalmologic findings are the least frequent findings in all reports. Amongst the Turkish patients our patient was the only patient with hearing loss. In addition, hypothyroidism in Case 2, and angiokeratoma only on the tongue and gingiva in case 12 were the remarkable distinct findings.

In our patient, a striking finding was the positive sweat chloride test. Several authors have noted possible links between fucosidosis and CF. Both disorders are associated with high sweat electrolytes and recurrent infections of the respiratory tract without a recognized defect in systemic immunity.²¹ Fucosidosis patients often have recurrent infections confined to areas of mucus-secreting ciliated epithelia. It was proposed that the terminal sugars fucose and sialic acid play a major role in defining the

viscoelasticity of mucus. Therefore, alterations in the enzymatic cleavage of these sugars affect mucus cross-linking and its viscoelasticity. Without cross-linking, cilia would flail about ineffectively in watery secretions.⁸

Classical MRI findings include bilateral globi pallidi hyperintensities on T1- and marked hypointensity on T2-weighted images. In addition, there may be diffuse symmetric white matter hyperintensities on T2-weighted images with normal appearance on T1-weighted images, indicative of hypomyelination.⁷ In Turkish patients all of the MRIs were abnormal, and the manifestations were heterogenous (Table II). In case 12 there were hyperintense signal alterations on T1-weighted imaging and hypointense signal alterations on T2-weighted imaging in bilateral globus pallidus, substantia nigra, and nucleus ruber. Corpus callosum thinning and superior vermian atrophy was observed. This finding caused misdiagnosis of the elder brother as neurodegeneration with brain iron accumulation disorders (NBIA) which is one of the diseases that can present itself with the same bilateral pallidal hypointensity image on T2; whereas, it does not cause hypomyelination and atrophy like fucosidosis.¹⁹ In case 2 in addition to cortical atrophy, focal nodular signal abnormalities in the brainstem on T2- weighted images were shown. Interestingly, in 3 siblings reported by

Table II. Clinical, molecular and radiologic features of Turkish patients.

References	Case No	Sex	Age of Onset (y)	Consang.	Developmental history	Enzyme analysis/Mutations	Cranial Imaging
Seo et al. ¹³	1	M	1	+	Diagnosed with fucosidosis at the age of 1 due to progressive neurological regression, spasticity, contractures, coarse facies, hepatosplenomegaly, growth retardation, and angiokeratoma corporis diffusum. He did not develop any speech skills and was bedridden until his death at the age of 22	Negligible enzyme activity in cultured skin fibroblasts/ c.773delA, p.(Glu258Glyfs*3)	NA
Mungan et al. ¹⁴	2	M	1,5	+	He smiled to his mother at three months, sat with support at 12 months, and walked at 18 months. Afterwards his developmental delay became more obvious. He developmentally regressed, losing his ability to walk. He never uttered any meaningful words. His past medical history was also remarkable for recurrent pulmonary infections and myoclonic seizures	No enzyme activity in leukocytes/NA	Cortical atrophy, and focal nodular signal abnormalities in the brainstem on T2- weighted images
Kanitaksis et al. ¹⁵	3	F	9	+	She presented severe growth and mental retardation and angiokeratomas predominating over the lower trunk, the abdominal wall, the buttocks, external genitalia, and upper thighs. Smaller, lesions were also found on the gingiva and the lips	Almost complete absence of leukocyte enzyme lactivity/ NA	NA
Öner et al. ¹⁶	4	F	6	+	She demonstrated moderate growth and mental retardation until 3 years of age, never developing expressive language or walking without support. She then showed rapid developmental regression and psychomotor deterioration, subsequently becoming severely spastic with dystonic movements of her right arm and jaw and losing all psychosocial responses	Almost complete absence of leukocyte enzyme activity/ NA	Symmetrical hyperintensity in the periventricular and subcortical white matter on T2-weighted images, hyperintensity on T1- and hypointensity on T2-weighted imaging in bilateral globus pallidus,

Consang: consanguinity, y: year, m:month, a and b indicate siblings, NA: Non available

Table II. Continued.

References	Case No	Sex	Age of Onset (y)	Consang.	Developmental history	Enzyme analysis/Mutations	Cranial Imaging
Kılıç et al. ¹⁷	5 ^a	F	8	+	Mental Motor retardation, subsequently psychomotor deterioration	Low enzyme activity in cultured fibroblast cells/NA	Atrophy of periventricular white matter and hypointensities in thalamus
	6 ^a	F	16	+	Mental Motor retardation, subsequently psychomotor deterioration	Low enzyme activity in cultured fibroblast cells/NA	Atrophy of periventricular white matter and hypointensities in thalamus
	7 ^a	M	12	+	Mental Motor retardation, subsequently psychomotor deterioration	Low enzyme activity in cultured fibroblast cells/NA	Atrophy of periventricular white matter and hypointensities in thalamus
Kau et al. ¹	8 ^b	M	25 m	+	Developmental delay and regression	Low enzyme activity an mutation analysis	Increased cerebellar volume
	9 ^b	M	20 m	+	Developmental delay and regression milder than the twin brother case 8 and underwent bone marrow transplantation		Increased cerebellar volume
	10 ^b	M	2m	+	Diagnosed at 2 months of age and underwent bone marrow transplantation at 4 months of age		
Kılıç E et al. ¹⁸	11	M	12	+	His early developmental milestones were normal until two years of age . He then began to deteriorate in all developmental fields. At age 12, he had deteriorated significantly. There was intellectual delay with no speech, an inability to walk without support and an evident pattern of behavioral irritability.	Low leukocyte enzyme activity/NA	Symmetric periventricular white-matter hyperintensities contrasting with low intensities on the basal ganglia on T2 weighted images

Consang: consanguinity, y: year, m:month, a and b indicate siblings, NA: Non available

Table II. Continued.

References	Case No	Sex	Age of Onset (y)	Consang.	Developmental history	Enzyme analysis/Mutations	Cranial Imaging
Zübarioğlu et al. ¹⁹	12	F	7	-	She developed normal until 12 months of age. She began unsupported walk at 15 months and became gradually unsteady and was lost soon after 5 years of age. She had a complete loss of voluntary movements including head control. Choreathetoid movements, especially marked on arms. There were red streaks on gingivae and blue-brown spots on tongue	Low enzyme activity in plasma, leukocytes, and cultured fibroblasts	Mild hyperintensity in cerebral deep white matter and subcortical areas bilaterally, hyperintensity on T1- and hypointensity on T2-weighted imaging in bilateral globus pallidus, substantianigra, and nucleus ruber. Corpus callosum thinning and superior vermian atrophy was also observed
Ediz et al. ²⁰	13	M	4	+	He started to seat with unassisted after one year and to walk at age of 27 months. He could not speak any meaningful words. He was referred with recurrent upper respiratory tract infections in four months and treated like an asthma patient. There was hypertonicity in lower extremities	NA/ c.244C > T, p.Gln82* Nonsense mutation, truncated protein	Combination of hypointensity in the medial and lateral pallidal segments of the globus pallidus and hyperintensity in its laminae on T2-W.
Our patient	14	M	3,5	+	Developmental delay, seizure and neurologic regression at 2,5 years of age	Almost complete absence of leukocyte enzyme activity/ c. 1290_1299delGAAGTGGTCC (p. Lys431 fs)	Symmetric white-matter hyperintensities on T2 weighted images on periventricular and subcortical, centrum semiovale, corona radiata regions

Consang: consanguinity, y: year, m:month, a and b indicate siblings, NA: Non available

Kau et al.¹, increased cerebellar volume was detected in early childhood which was a novel finding.

The diagnosis of fucosidosis is made by measuring the enzyme activity or by molecular analysis of FUCA1 gene. To date, 41 pathological variants of FUCA1 gene encoding alpha L-fucosidase has been identified (www.hgmd.cf.ac.uk; updated 03 October 2021).²²

All mutations result in an almost total absence of enzyme activity suggesting that clinical heterogeneity is associated with not only residual enzyme activity but also with unknown factors.²²

In Turkish patients, only 3 molecular analysis was reported and our patient is one of them. We report a novel homozygous deletion leads to a frameshift mutation. The other mutations were nonsense and frameshift mutations.

The management of fucosidosis is challenging. There is still no approved therapy for neurologic findings of the disease and the main management strategy is supportive with physiotherapy and other allied health input. The multidisciplinary team usually involves metabolic physicians, physiotherapists, ophthalmologist, orthopedic, cardiology and neurology specialists. Enzyme replacement therapy via cerebrospinal fluid and substrate inhibition therapies are under preclinical stages. HSCT via umbilical cord blood and bone marrow transplantation are the treatment options. HSCT was applied in a small number of patients with fucosidosis with symptoms stabilization in some early diagnosed cases however the long-term results are controversial.⁸ In addition, individuals are often considered unsuitable for transplantation because they are diagnosed with advanced disease. HSCT was applied to 2 of the Turkish patients. They were siblings and case 9 had mild disease, and case 10 underwent HSCT at the age of four months before the development of clinical manifestations. However, there was no data regarding their neurologic progress. HSCT in our patient is controversial as he has neurologic manifestations.

We report a fucosidosis patient with seizure onset developmental regression. In lysosomal storage diseases seizure is generally a feature of late stages of the disease. The patient is also distinguished from the other patients by having hearing loss and a hernia. In addition, in our patient despite symmetrical periventricular white matter abnormalities, there was no globus pallidus involvement.

In Turkish patients, there were no clinical and radiologic findings to distinguish them from those in the literature. Patients had common clinical features such as coarse face, developmental delay, neurologic regression, and non-common features such as angiokeratoma, seizure and hearing loss. On the other hand, radiologic features also showed heterogeneity among the patients; some patients only had hypomyelination while some also had basal ganglia and brain stem involvement.

Ethical approval

Written informed consent was obtained from the parents of the child.

Author contribution

The authors confirm contribution to the paper as follows: study conception and design: MEŞ, SU; data collection: MEŞ, SU; analysis and interpretation of results: MEŞ; draft manuscript preparation: MEŞ. All authors reviewed the results and approved the final version of the manuscript.

Source of funding

The authors declare the study received no funding.

Conflict of interest

The authors declare that there is no conflict of interest.

REFERENCES

1. Kau T, Karlo C, Güngör T, et al. Increased cerebellar volume in the early stage of fucosidosis: a case control study. *Neuroradiology* 2011; 53: 509-516. <https://doi.org/10.1007/s00234-011-0855-1>
2. Willems PJ, Gatti R, Darby JK, et al. Fucosidosis revisited: a review of 77 patients. *Am J Med Genet* 1991; 38: 111-131. <https://doi.org/10.1002/ajmg.1320380125>
3. Durand P, Borrone C, Della Cella G. A new mucopolysaccharide lipidstorage disease? *The Lancet* 1966; 288: 1313-1314. [https://doi.org/10.1016/s0140-6736\(66\)91718-1](https://doi.org/10.1016/s0140-6736(66)91718-1)
4. Loeb H, Tondeur M, Jonniaux G, Mockel-Pohl S, Vamos-Hurwitz E. Biochemical and ultrastructural studies in a case of mucopolysaccharidosis "F" (fucosidosis). *Helv Paediatr Acta* 1969; 24: 519-537.
5. Wood S. A sensitive fluorometric assay for alpha-KL-fucosidase. *Clin Chim Acta* 1975; 58: 251-256. [https://doi.org/10.1016/0009-8981\(75\)90444-1](https://doi.org/10.1016/0009-8981(75)90444-1)
6. Kretz KA, Cripe D, Carson GS, Fukushima H, O'Brien JS. Structure and sequence of the human α -L-fucosidase gene and pseudogene. *Genomics* 1992; 12: 276-280. [https://doi.org/10.1016/0888-7543\(92\)90374-2](https://doi.org/10.1016/0888-7543(92)90374-2)
7. Wali G, Wali GM, Sue CM, Kumar KR. A novel homozygous mutation in the FUCA1 gene highlighting fucosidosis as a cause of dystonia: case report and literature review. *Neuropediatrics* 2019; 50: 248-252. <https://doi.org/10.1055/s-0039-1684052>
8. Stepien KM, Ciara E, Jezela-Stanek A. Fucosidosis-clinical manifestation, long-term outcomes, and genetic profile-review and case series. *Genes (Basel)* 2020; 11: 1383. <https://doi.org/10.3390/genes11111383>
9. Willems PJ, Seo HC, Coucke P, Tonlorenzi R, O'Brien JS. Spectrum of mutations in fucosidosis. *Eur J Hum Genet* 1999; 7: 60-67. <https://doi.org/10.1038/sj.ejhg.5200272>
10. Lin SP, Chang JH, de la Cadena MP, Chang TF, Lee-Chen GJ. Mutation identification and characterization of a Taiwanese patient with fucosidosis. *J Hum Genet* 2007; 52: 553-556. <https://doi.org/10.1007/s10038-007-0136-3>
11. Wang L, Yang M, Hong S, Tang T, Zhuang J, Huang H. Fucosidosis in a Chinese boy: a case report and literature review. *J Int Med Res* 2020; 48: 300060520911269. <https://doi.org/10.1177/0300060520911269>
12. Malatt C, Koning JL, Naheedy J. Skeletal and brain abnormalities in fucosidosis, a rare lysosomal storage disorder. *J Radiol Case Rep* 2015; 9: 30-38. <https://doi.org/10.3941/jrcr.v9i5.2149>
13. Seo HC, Kunze J, Willems PJ, Kim AH, Hanefeld F, O'Brien JS. A single-base deletion mutation in a Turkish patient with fucosidosis. *Hum Mutat* 1994; 3: 407-408. <https://doi.org/10.1002/humu.1380030416>
14. Onenli-Mungan N, Ozer G, Altunbaşak S, et al. Fucosidosis with hypothyroidism: a case report. *Turk J Pediatr* 2004; 46: 170-173.
15. Kanitakis J, Allombert C, Doebelin B, et al. Fucosidosis with angiokeratoma. Immunohistochemical & electronmicroscopic study of a new case and literature review. *J Cutan Pathol* 2005; 32: 506-511. <https://doi.org/10.1111/j.0303-6987.2005.00366.x>
16. Oner AY, Cansu A, Akpek S, Serdaroglu A. Fucosidosis: MRI and MRS findings. *Pediatr Radiol* 2007; 37: 1050-1052. <https://doi.org/10.1007/s00247-007-0572-4>
17. IF-ELSE-Kılıç M, Sivri S, Kılıç E, et al. Fucosidosis tanısı alan 3 olgunun fenotipik spektrumu. *J LSD* 2010; 2: 66-67.
18. Kılıç E, Kılıç M, Ütine GE, Sivri S, Coskun T, Alanay Y. A case of fucosidosis type II: diagnosed with dysmorphological and radiological findings. *Turk J Pediatr* 2014; 56: 430-433.
19. Zubarioglu T, Kiykim E, Zeybek CA, et al. Clinical and neuroradiological approach to fucosidosis in a child with atypical presentation. *Ann Indian Acad Neurol* 2015; 18: 471-474. <https://doi.org/10.4103/0972-2327.160090>
20. Ediz SS, Aralasmak A, Yılmaz TF, Toprak H, Yesil G, Alkan A. MRI and MRS findings in fucosidosis; a rare lysosomal storage disease. *Brain Dev* 2016; 38: 435-438. <https://doi.org/10.1016/j.braindev.2015.09.013>
21. Rubin BK, MacLeod PM, Sturgess J, King M. Recurrent respiratory infections in a child with fucosidosis: is the mucus too thin for effective transport? *Pediatr Pulmonol* 1991; 10: 304-309. <https://doi.org/10.1002/ppul.1950100415>
22. HGMD Professional. Available at: <http://www.hgmd.cf.ac.uk/ac/index.php>